OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2023-12-31-accounts

Company Number 06884476

YORK AGAINST CANCER

A company limited by guarantee and

A registered charity number 1130835

REPORT AND ACCOUNTS

For the year ended

31 December 2023

HPH Chartered Accountants 54 Bootham York YO30 7XZ

YORK AGAINST CANCER

CONTENTS
Page
Chairman’s Report 1
Trustees’ Report 2 ‐ 18
Auditor’s Report 19 – 22
Statement of Financial Activities 23
Balance Sheet 24
Cash Flow Statement 25
Notes to the Financial Statements 26 ‐ 36

YORK AGAINST CANCER

CHAIRMAN’S REPORT 2023

2023 saw the Charity continue to provide the vital and valuable support that makes it so unique. A number of projects progressed and the important £680,000 donation to the York and Scarborough Hospitals NHS Foundation Trust to enable it to acquire a new robotic surgical system, has proven to be an important investment in helping not only local cancer patients, but also helping the Hospital Trust ensure that more cancer expertise can be retained closer to home. The cancer support centre, The Leveson Centre ‐ named after one of the Charity’s founders Professor Steve Leveson ‐ was completed and has quickly become a very important part of what the Charity strives to provide. It is now our most visible location and delivers a wide range of services for those affected by cancer.

The mini‐bus continues to offer a vital service to many who need to travel to Leeds for radiotherapy treatment, while the respite home at Filey remains a haven for those able to use it. The Filey property has recently been supplemented by a smaller property at Yapham which is just outside Pocklington and we would like to thank Phil and Hazel Arnold for their very generous support which allows more people to benefit from that important ‘time away’. The Jack Birch Unit at York University continues to provide internationally recognised research into cancers, research which remains an important part of what York Against Cancer is all about.

Once again, we sadly lost a number of our volunteers and supporters throughout the year, and our thoughts go out to their families and friends. Each of them supported the work of the Charity, and helped it continue to provide the important services and funding for research that we are recognised for.

Our small office and retail team, our mini‐bus drivers, the Leveson Centre team and our army of volunteers continue their hard work week to week, and to them, and Board colleagues, I would like to pass on my grateful thanks for your continuing support and promotion of the Charity.

With the completion of the Leveson Centre our longer‐term commitments are now significant, and the need to look forward and plan for our current and future funding requirements goes on to ensure we remain focused and able to fund the important services for people impacted by cancer.

It is now 36 years since York Against Cancer was created. Its longevity is very much down to the vision of those who established the Charity all those years ago, but it is also a testament to the work undertaken by everybody who is or has been involved over the years.

Ian Yeowart Chair York Against Cancer

www.yorkagainstcancerorg.uk 1

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

The Directors (who are also the Trustees of the Charity and are listed below) are pleased to present their report of the Charitable Company for the year ended 31 December 2023.

Objectives and activities

The objects of the Charity are to raise funds to:

  1. Foster and promote joint research between clinicians and research scientists in York and wider area and, by encouraging a more effective exchange of ideas and information, to advance the alleviation and cure of cancer.

  2. Support treatment of cancer patients at York Hospital and the local area.

  3. Fund education and information about cancer for patients and their families and the wider public.

The Trustees believe they have complied with the duty in section 4 of the 2006 Charities Act to have due regard to guidance published by the Charity Commission in respect of public benefit.

Aims and strategies

The Charity aims to provide support to cancer patients and the community through the: ‐

Achievements and performance

The Office Team

The office team have settled into their new working environment within York Stadium and are building business relationships with other key stakeholders. They continue to deal with the complex operational challenges that arise, and they do this with great resolve and in a positive manner. Each member of the team has their own responsibilities; however, they support each other with day‐to‐day tasks, ensuring the smooth operation of the charity and everyone receives the support they need. They respond quickly to any requests and challenges they are faced with, and this is recognised as a key strength of the team.

www.yorkagainstcancerorg.uk 2

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

Care group report 2023

The purpose of the Care group is to consider applications both external and internal for “care” projects to be funded by York Against Cancer and to make recommendations to the Board of Trustees for ratification.

The group comprises of YAC Trustees and representatives from different areas of the charity, who have the expertise to make judgements on the value of the proposed projects.

There is a stringent application process which is adhered to; a standard application form is used and the following pathway.

www.yorkagainstcancerorg.uk 3

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

Not all applications are successful but the ones that are, must show clear evidence that the project is of value to patients, has longevity and fulfils the over‐arching aims of the charity.

Please see below a list of successful projects funded in 2023.

** Some projects have a fixed term contract, (usually 2 or 3 years) these are be reassessed before being renewed or otherwise.

This robust approach for the consideration of funding care projects shows due diligence given to the spending of money which has been donated or fundraised for by the general public.

I would like to thank my colleagues who sit on the Care group for their time and hard work during 2023.

Mike Stower

Chair of the Care group

www.yorkagainstcancerorg.uk 4

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

SUPPORT AND CARE SERVICE ACTIVITIES

Services and posts supported by York Against Cancer

In addition to the team directly employed by the charity there are other support workers whose salary costs are paid by York Against Cancer. These posts are as follows, which illustrates the range of activities supported by the Board:

The charity continues to fund a cancer benefits advice service providing holistic financial advice for cancer patients in the Scarborough area: ensuring they receive the financial help to which they are entitled.

The main issues faced by clients by proportion are shown as follows: ‐

ISSUE – Pa�ents Concerns 2022‐23 2021‐2022
· Benefts 97% 97%
· Charitable applica�ons 28.5% 15%
· Health & CommunityCare 5% 5%
· Debt 2% 2%
· Financial services 3.5% 4%
· Employment 1.5% 2%
· Housing 2% 5%
· Travel & Transport 5% 6%

As demonstrated by these figures the issue of Benefits remains at the top of the agenda, affecting 97% of clients.

During 2023 the majority (77%) of clients were aged between 55 and 84 years old; although, 14% of our clients were under 55 and 9% aged 85 or over.

Pressures of the escalating cost of living directly impact cancer patients as they fall into the most vulnerable of categories and as a result there was a substantial increase in the need for charitable support and food banks. The number of clients requiring this type of assistance for the previous year was 70, this year the number has more than doubled to 160.

An agreement was signed in October 2023 for the York service and a full report will be available for the 2024 annual report.

www.yorkagainstcancerorg.uk 5

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

Teenage Psychology Support

YAC funds Dr Rebecca Donaldson, a Teenage Psychologist who supports young people when they or someone they know is affected by cancer. This service is funded on a need basis, during 2023 the charity spent £16k on this service. Referrals are received from Clinical Nurse Specialists, Oncologists, G.P’s and the Leveson Centre. Dr Donaldson (Becky) is often accompanied by her Therapy dog, Luna.

Adult Psychology

Dr Jo McVey, Adult Psychologist started seeing patients in October 2023 in the Leveson Centre, a full report will be available for the 2024 annual report.

Mobile Chemotherapy Unit

The Mobile Chemotherapy Unit (MCU) takes chemotherapy services to the wider areas of the York & Scarborough Hospital Trust, in Malton, Selby, Scarborough and Bridlington, this has enabled the charity to widen its reach. The MCU has helped thousands of patients avoid the time‐consuming and tiring journeys to the hospital in York. During 2023 we continued to fund the cost of servicing and repairs to keep the MCU on the road.

Minibus

Our minibus service continues to be popular; we provide free transport for patients going to St James hospital in Leeds for radiotherapy treatments. During 2023 we provided 73 individual patients with transport to Leeds – radiotherapy is given daily (Mon‐Fri) and length of treatments can range from 3 to 7 weeks. If the demand is high we use volunteer drivers and if demand is low, we use the YAC car, making the service more efficient.

www.yorkagainstcancerorg.uk 6

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

‘Just to say thank you. The bus to Leeds was a God send. It was good fun with the people on the bus.’

‘Thank you for your kindness and help getting to St James hospital.’

The provision of patient transport to Rapid Diagnostic appointments.

We work closely with the Rapid Diagnostic department offering transport to patients who need to get to their diagnostic appointments which are not always at their nearest hospital.

We have provided transport to these types of appointments since 2021 and in the last 12 months have helped 29 patients from York, Malton and Scarborough at a cost of £2900 p.a.

Respite Properties

Our Filey house provides valuable respite breaks for cancer patients; during 2023 156 patients visited the property along with family or friends.

In April, local couple Hazel and Phil Arnold completed a full renovation of one of their farm buildings, situated in Yapham, which is 4 miles from Pocklington. They have offered us full use of their property as a second respite offering. The cottage sleeps 2 people and is a valuable addition to the Filey house.

We encourage feedback from service users to ensure we get to know of any issues and so we can keep the standards high. If any improvements need addressing, we act on these quickly. On booking a break we ask for a deposit; visitors can request this be returned but many users donate it to us as a way of a thank you.

----- Start of picture text -----
Thank you so much, our stay
in Filey was wonderful and
beyond our expectations.
----- End of picture text -----

Thank you for all you do for cancer patients. We had an amazing break and will treasure all the memories.

www.yorkagainstcancerorg.uk 7

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

The Leveson Centre – providing cancer support services

On 6th February 2023 the doors of the Leveson Centre opened providing cancer patients, their friends and family somewhere to access support, care and information whilst going through cancer. The ‘look and feel’ of the Centre was intentionally non‐clinical, the space is welcoming, friendly, calming, and inclusive.

The footfall during 2023 went from 173 visitors in its first month to over 600 per month by the end of the year. We record how many patients, family members, friends and hospital professionals visit each day and record whether the visit is a planned appointment or a walk‐ in. This information provides the data to ensure we have our staffing and volunteer numbers correct.

A range of activities are on offer in the Centre, this has grown gradually during 2023. We listen to visitors’ feedback and have grown our activity accordingly.

Also, Psychology appointments are available at the Leveson Centre as detailed on page 3 of this report.

www.yorkagainstcancerorg.uk 8

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

RESEARCH ACTIVITIES

Clinical Research Nurse and Assistant posts at York Hospital

During 2023 funding support to clinical trials has enabled four new studies, including Haematology, Colorectal, Breast and early cancer detection. There were eleven cancer studies open, seven of these hit the target number of recruits which would not have been achieved without the YAC funding.

The funding was also instrumental in the continuation of the PINPOINT Study. This study is a simple blood test, which seeks to become another tool in primary care to triage those who are being considered for the two‐week wait cancer pathway. This study works in collaboration with GPs and the Rapid Diagnostic Centre, it uses biomarkers in the blood to provide a ‘Pinpoint score’. The study recruited 664 participants (as of 9/11/23) of which 41 were found to have cancer.

Our funding continues to provide essential support to many of the long‐standing studies, many of which continue above and beyond 10+ years.

Jack Birch Unit (University of York)

The Charity is committed to another 9 months supporting the work of the Jack Birch Unit. The roles supported by York Against Cancer are: ‐

Director of the Jack Birch Unit

Assistant Director

Laboratory technician Administrative assistant

Research Fellow in Informatics at the Jack Birch Unit is also being supported from 2019 to 2024.

Jack Birch Unit of Molecular Carcinogenesis – Annual Report 2023

York Against Cancer provides funds in the form of a generous five‐year programme grant to support research in the Jack Birch Unit, where we have built unique expertise in urothelial (bladder) cancer research. Although one of the top 10 common cancers of ageing, bladder cancer typically receives less research funding than other cancers. This means that York Against Cancer’s funding is able to make particular research impact.

www.yorkagainstcancerorg.uk 9

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

One important aspect of our work in the JBU is the training of the next generation of scientists and it has been a timely year to mark the significant progress being made by two of JBU’s outstanding researchers, Dr Simon Baker and Dr Andrew Mason, as they nurture their own research groups within the JBU. A reorganisation of the JBU website* was carried out to reflect their changing status as group leaders. Simon holds a fellowship from Kidney Research UK and is studying a common virus as a possible cause of bladder cancer. Andrew, who was originally appointed to the YAC 30[th] Anniversary Fellowship, now holds a lectureship and studies data collected from urothelial cancers in the UK and worldwide. Indeed, Andrew is himself now involved in training the next generation of students in cancer informatics, with two of his group receiving prizes at one of the scientific meetings attended. Under other staff news. Dr Jenny Baker (née Hinley) who had studied her PhD in the JBU, rejoined after a stint away and Denise Alaniz Barraza from Mexico joined the group for 12 weeks’ research experience after completing her Master’s degree in the Department of Biology. Our YAC‐funded PhD student, Ryan Ellison left towards the end of the year to write up his thesis and was replaced by George Hatton, who prior to becoming the new YAC PhD Tea Party for YAC supporters in the student, completed his final year project in the Guildhall. JBU as part of his Integrated Master’s degree.

One of the year’s highlights occurred in March, when Ian Yeowart and Julie Russell visited the University to meet the Vice Chancellor. Professor Charlie Jeffrey thanked York Against Cancer for their ongoing support of the Jack Birch Unit and discussed future opportunities for partnership with the University under the 2030 vision of a “University for Public Good”. This was followed by a series of research presentations in the JBU. Later, in April, a tea party was held at the Guildhall in York to celebrate YAC’s induction into the University’s College of Benefactors and to thank YAC supporters and fundraisers for the fantastic job they do.

Finally, as JBU Director, I would like to thank York Against Cancer Trustees, fundraisers and supporters for the research support we receive. I further thank all our scientific and clinical collaborators for the important contribution they make to the quality and output of our research.

Professor Jenny Southgate, Director, Jack Birch Unit of Molecular Carcinogenesis, University of York

www.yorkagainstcancerorg.uk 10

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

EDUCATION ACTIVITIES

The Cancer Awareness and Prevention group continues to work to spread information about cancer across as wide a range of the public as possible with an emphasis on young people.

York Against Cancer Awareness and Education Committee Report 2023

Our committed team has continued to meet regularly, either face to face or via zoom.

Dr Simon Baker, Research Scientist at the Jack Birch Unit, has taken the lead with the Enthuse partnership project, working with the National STEM Learning Centre (NSLC) and 6 local secondary schools (spreading out from the city to include Selby and Malton). The partnership aims to train teachers to be more confident in teaching cancer‐related topics and a cancer‐focussed programme of continuing professional development has been delivered by the NSLC over the last two years. The partnership has engaged Amazelab who develop engaging, creative teaching resources relating to DNA and cell biology which have received very positive reviews from the schools.

Another key feature of the project is to teach young people about cancer research using practical experiments with scientists from the Jack Birch Unit in the state‐of‐the‐art University of York teaching laboratories. We have taken students from three schools through a DNA mutation practical in the labs followed by bioinformatics work package created by Dr Andrew Mason. Again, the new practical designed around a specific cancer‐causing mutation in the p53 gene was very well received. We are now looking to cherry‐pick the best bits of our Enthuse partnership and develop an ambitious new phase of this project aiming to reach more schools for even more impact. Every teacher we reach can influence hundreds of students and their families.

We have distributed 1300 sun hats to 37 primary schools in the York and surrounding area. Our committed volunteers helped with the delivery to the participating schools.

Before Covid we provided Primary schools with books about how to talk to children about cancer, they were popular and after seeking feedback from the schools, the A & E group plan to repeat this project but with new and up to date books.

We held an awareness day in York City Centre in October, this gave us the opportunity to talk to people about cancer awareness and about the work of the charity.

As always, the priority of the group is to ensure making the biggest difference with our limited resource. Our focus has been to look at local cancer screening uptakes and to compare with the national statistics. This year we looked specifically at bowel cancer screening as it was deemed this screening could be improved upon in Yorkshire. A drinks mat was designed and handed out at events which included the awareness day.

The group is also looking at the local geography and underrepresented groups comparing cancer statistics looking for areas which need our focus. We have contacts within the clinical commissioning group from whom we can get the detailed data on which we can act on in the future.

We are looking at widening our reach across the whole of York and North and East of Yorkshire in collaboration with the communications committee.

Thank you to the YAC team and the Awareness and Education group members.

www.yorkagainstcancerorg.uk 11

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

FUNDRAISING

The retail outlets, at Huntington and the Hospital have continued to be an invaluable source of income and the hospital shop provides a very useful ‘shop front’ for the charity. The sterling work done by our volunteers; and our staff in the office has yet again given up many hours in the evening and at weekends to spread the message about York Against Cancer. The links with the local business community have again proved a great benefit to the charity. With all these efforts from our employed staff and volunteers the charity is able to provide more much‐needed support to many in the local community.

York Against Cancer is committed to maintaining high standards of fundraising and retail activity. The Charity is registered with the Fundraising Regulator. The Charity has recognised and begun to put in place a comprehensive policy for fundraising. The Charity does not use any third parties to act on its behalf in relation to fundraising. No complaints were received by the charity during 2023 in relation to its fundraising activities.

Fundraising report 2023

We have again been very lucky with the fundraising support we have received from individuals, businesses, organisations, and groups in the last 12 months.

As well as holding our own events at which we have been supported brilliantly by our volunteers, there are events that are organised on our behalf. On many occasions the first we know about an event is when we see an amount of money come into the bank account or we are handed a cheque. Every pound received helps us to continue with services we already provide and to plan what we may do more to help, support and care for cancer patients. We really cannot do what we do without the support of fundraising.

Here are a few of our events and the fantastic amounts raised.

www.yorkagainstcancerorg.uk 12

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 202

When we are talking to prospective fundraisers, we like to tell them how the money they raise will be spent. The following graphic is used for this purpose.

FUTURE PLANNING

The Board have continued their consistently adopted policy of only making commitments when the finance for these is already in place. The Board are mindful of the responsibility of ensuring that the generous donations received are used in the most effective manner possible to meet with the aims of the charity. With a sudden increase in legacies over the last few years the board established a Finance Sub‐group to consider the most effective way to manage the funds for the future of the charity. The Board has agreed with the recommendations of the sub‐group that a significant proportion of funds should be invested to provide for both future security of the charity and to ensure that the capital is used most effectively and to be available when future projects are considered and to ensure that the long‐term plans and services the charity provides can be continued into the foreseeable future.

www.yorkagainstcancerorg.uk 13

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

Structure, Governance and Management

The charity was incorporated on 22 April 2009 and its governing document is the memorandum and articles of association. The charity is a company limited by guarantee.

The charity is governed by a Board of Directors, supported by working groups as required. The Board members are all Trustees and include Officers of the Charity.

The Board meets four times a year and the various working groups meet as required during the year.

The members of the Board are volunteers. New Board members are elected by the existing members up to a maximum of twelve in total.

Trustee Induction and Training

New Trustees are briefed on their legal obligations under charity law, the committee and decision‐ making processes, the business plan and recent financial performance of the Charity. During their induction they meet key employees and other trustees. Trustees are encouraged to attend appropriate external training events where these will facilitate the undertaking of their role. At the end of each three tenure the trustees are required to update their trustee training.

Organisational Structure

The Board delegates the day‐to‐day management of the affairs of the Charity to Chief Executive Officer with assistance from a Board member, Tarnia Hudson, who serves as the Honorary Administrator.

Board membership

In March 2013 the Board adopted, by unanimous agreement, a protocol to introduce a three‐year rule from that date. Board members continue to actively seek new trustees, taking into consideration a good mix of professional skills including business, education and medical. A term of office for a director is 3 years, after which time he/she may be re‐elected for a further 3‐year term (details of current terms of office available on request).

Remuneration of key personnel

All members of staff employed by the charity have an annual appraisal in January following which salaries are set for the following 12 months. The appraisals are carried out by the Chief Executive Officer.

No Board member received any income or expenses for their work for the charity.

Related parties

The Charity owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited, a company registered in England and Wales. The subsidiary is used for the raising of funds for the Charity through the sale of bought in goods through the Charity’s two shops.

www.yorkagainstcancerorg.uk 14

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

Risk management

The Trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the Charity and continues to take measures to reduce those risks to an acceptable minimum. The policy of only making new commitments when the funds are in hand is a very practical way of eliminating unnecessary financial risks. By its very nature a charity relies on fundraising, donations and legacies which can vary a great deal. Ongoing commitments are to our staff and to a range of time limited research and care projects.

The Board is proactive in identifying projects on which to spend its reserves, ensuring to find effective ways in which to fulfil the aims of York Against Cancer, whilst at the same time investing some funds to provide for future security.

Financial review and polices

The Charity’s funds in 2023 decreased by £336,178 (2022 ‐ decreased by £380,991). Prior to any adjustment for investments, the Charity made a deficit of £329,816 (2022 – deficit of £351,405). The largest new commitment in the year was £160,000 for the expansion of the Cancer Benefit Advice Service into the York Area.

The detail of funding of services and care activities can be found in note 6.

The principal funding sources are fund‐raising, the trading shops, donations, and legacies. Gross income in 2023 amounted to £763,604 (2022 £1,468,175). These funds support the key objectives of the Charity, namely, to fund clinical research, to support people with cancer and to fund education about the disease.

The charity has continued to benefit from legacies during the year, and we are immensely grateful to the generous donors. Legacy income is unpredictable and is another reason why the charity must husband its resources in the most effective way to enable the services we provide to both continue and develop.

Investment powers and policy

The Trustees have a general power of investment and so have the discretion to invest in such investment assets as they see fit. The Trustees have set a policy that sufficient of the ‘free reserves’ should be invested to retain a reasonable liquidity to meet grant commitments.

Our policy is a medium low risk approach for the growth of the portfolio of investments. The investment managers have discretion about how the investments are managed within the policy parameters set by the Trustees.

The Investment Group oversees the investment management of the Charity’s funds. The services of HSBC Private Bank and Ruffer were retained as investment managers during 2023. Funds not invested are held on deposit to earn interest.

www.yorkagainstcancerorg.uk 15

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

The total return on the investment portfolio managed by HSBC for the year ended 31 December 2023, before fees, was 3.27% (2022 ‐7.53%). The total return on investment portfolio managed by Ruffer for the year ended 31 December 2023, before fees, was ‐6.6% (2022 7.4%).

Reserves Policy

The reserves policy is to ensure the charity holds sufficient funds for the continuation of our support services, whilst maintaining the ability to commitment to future projects. When the Leveson Centre was being planned the trustees understood that this would change the funding model needed for the Charity. The Leveson Centre will increase the operating costs of the charity as we bare all the costs for running the centre.

Cash reserves are accumulated before making a binding commitment to fund set term projects. The total funds held as at 31 December 2023 are £4,060,891 (2022 £4,397,069).

The Board is very mindful that the charity is wholly reliant on donated income and therefore has designated funds for future projects which are under consideration. This ensures its undesignated funds reflect the true level of reserves we hold for future operating commitments.

Undesignated Fund

These are reserves retained to provide working capital and funds for future projects. At the end of the financial year, the unrestricted undesignated reserves were £1,093,281 (2022 £1,151,686). The level of free reserves is £697,568 (after excluding lease commitments which we expect to be covered from future annual income). This is the equivalent of 12 months of our budgeted undesignated operating costs. It is the charity’s policy to hold 12 months of our operating costs as the charity is largely reliant on donated and legacy income.

Excess reserves will be available for additional fixed term projects or grants not already under consideration.

Designated Funds

Designated funds are part of the unrestricted funds which trustees have earmarked for assets held for the use in the charity and specific projects. At the year end, The Charity had consolidated designated funds of £2,852,276 (2022 £3,109,980) details of which are given in Note 16 of the financial statements.

Restricted Funds

Restricted funds represent monies raised by the Charity from public appeals for specific projects. At the year end, the Charity had restricted funds of £115,334 (2022 £135,403) details of which are given in Note 17 to the financial statements.

www.yorkagainstcancerorg.uk 16

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

Directors and Trustees Responsibilities

The purpose of this statement is to distinguish the Directors’ and Trustees’ responsibilities for the financial statements from those of the auditors as stated in their report.

Company and charity law require the Directors and Trustees to prepare financial statements which give a true and fair view of the Charitable Company’s state of affairs at the end of its financial activities for that year. In preparing those financial statements the Trustees are required to:

The Directors and Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Charitable Company and enables them to ensure that the financial statements comply with the Companies Act 2006 and applicable charity law. They are also responsible for safeguarding the assets of the Charitable Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Directors and Trustees are aware:

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

Approved by the Board on 6 August 2024 and signed on its behalf by:

Ian Yeowart Director and Trustee

www.yorkagainstcancerorg.uk 17

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

Reference and administrative details

Registered Charity number 1130835 Company Limited number 06884476 by Guarantee

Principal Office and Trading Address East Stand York Community Stadium Kathryn Avenue Huntington York YO32 9AF

Company Secretary Julie Pamela Russell

Directors and Trustees Andrew Proctor Dr Lynn Bartram (resigned 11 July 2023) Angela Darby Michael Sweet Rachel Goddard Robert Onyett Michael John Stower Tarnia Hudson Ian Yeowart Prof Stephen Leveson Sarah Wearing Michael Patrick Shepherd (resigned 25 October 2023) William Mark Sessions (resigned 11 July 2023)

Trustee’s protocol available on request

Accountants HPH Auditors Henton & Co LLP Chartered Accountants Chartered Accountants 54 Bootham 124 Acomb Road York Holgate YO30 7XZ York YO24 4EY Bankers National Westminster Bank Solicitors Harrowells 1 Market Street Moorgate House York Clifton Moorgate YO1 8SR York YO30 4WY Investment Advisors HSBC Global Asset Ruffer LLP Management 80 Victoria Street 78 St James’s Street London London SW1E 5JL SW1A 1EJ

www.yorkagainstcancerorg.uk 18

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER

YEAR ENDED 31 DECEMBER 2023

Opinion

We have audited the financial statements of York Against Cancer (the 'parent charitable company') and its subsidiary (the ‘group’) for the year ended 31 December 2023 which comprise the group statement of financial activities, the group balance sheet, the charitable company balance sheet, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group’s and parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

www.yorkagainstcancerorg.uk 19

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER

YEAR ENDED 31 DECEMBER 2023

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matter on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the trustees' report.

We have nothing to report in respect of the following matters where the Companies Act 2006 required us to report to you if, in our opinion:

Responsibilities of the trustees

As explained more fully in the trustees' responsibilities statement, the trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

www.yorkagainstcancerorg.uk 20

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER YEAR ENDED 31 DECEMBER 2023

Irregularities, including fraud, are instances of non‐compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

www.yorkagainstcancerorg.uk 21

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER

YEAR ENDED 31 DECEMBER 2023

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the Charity's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Charity's members those matters we are required to state to them in an auditors report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charity's members as a body, for our audit work, for this report, or for the opinions we have formed.

………………………………………………..

Brett Davis (Senior Statutory Auditor)

For and on behalf of Henton & Co LLP

Chartered Accountants Statutory Auditor 124 Acomb Road York YO24 4EY

Date: 6 August 2024

www.yorkagainstcancerorg.uk 22

YORK AGAINST CANCER

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES AND INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 DECEMBER 2023

Note
Income and endowments from:
Donations and legacies
2
Other trading activities
3
Investments
4
Total
Expenditure on:
Raising funds
5
Charitable activities
6
Total
Net income/(expenditure)
before gains on investments
Net (losses)/gains on investments
11
Net income/(expenditure)
Transfers between funds
16
Net movement in funds
Reconciliation of funds:
Total funds brought forward
Total funds carried forward		 General
Designated
Fund
Funds
£
£
430,182
-
287,169
-
46,153
-
763,504
-
321,182
-
457,120
294,949
778,302
294,949
(14,798)
(294,949)
(6,362)
-
(21,160)
(294,949)
(37,245)
37,245
(58,405)
(257,704)
1,151,686
3,109,980
1,093,281
£
2,852,276
£
Unrestricted		 Restricted
Funds
£
100
-
-
100
-
20,169
20,169
(20,069)
-
(20,069)
-
(20,069)
135,403
115,334
£		 Year ended
31 Dec
2023
£
430,282
287,169
46,153
763,604
321,182
772,238
1,093,420
(329,816)
(6,362)
(336,178)
-
(336,178)
4,397,069
4,060,891
£		 Year ended
31 Dec
2022
£
1,169,842
261,895
36,438
1,468,175
259,611
1,559,969
1,819,580
(351,405)
(29,586)
(380,991)
-
(380,991)
4,778,060
4,397,069
£

The notes on pages 26 to 36 form part of these financial statements.

www.yorkagainstcancer.org.uk 23

YORK AGAINST CANCER (Registration number: 06884476)

BALANCE SHEET AS AT 31 DECEMBER 2023

FIXED ASSETS
Tangible Fixed Assets
12
Investments
11
CURRENT ASSETS
Stock
Debtors
13
Cash at Bank and in Hand
CREDITORS: amounts falling due
within one year
14
TOTAL ASSETS LESS CURRENT
LIABILITIES
CREDITORS: amounts falling due
after one year
15
NET ASSETS
THE FUNDS OF THE CHARITY
Unrestricted
Undesignated
18
Designated
16,18
Restricted
17,18
TOTAL CHARITY FUNDS
NET CURRENT ASSETS
Note		 Charity
2023
£
998,691
2,987,058
3,985,749
-
726,455
487,179
1,213,634
1,014,539
199,095
4,184,844
80,000
£ 4,104,844
1,171,819
2,817,691
115,334
£ 4,104,844		 Consolidated
2023
£
1,033,276
2,987,057
4,020,333
65,919
583,982
548,880
1,198,781
1,078,223
120,558
4,140,891
80,000
£ 4,060,891
1,093,281
2,852,276
115,334
4,060,891
£		 Charity
2022
£
826,241
3,516,498
4,342,739
-
1,043,825
811,874
1,855,699
1,055,560
800,139
5,142,878
731,410
£ 4,411,468
1,206,074
3,069,991
135,403
£ 4,411,468		 Consolidated
2022
£
866,230
3,516,497
4,382,727
60,521
912,677
863,649
1,836,847
1,091,095
745,752
5,128,479
731,410
£ 4,397,069
1,151,686
3,109,980
135,403
£ 4,397,069

Approved by the Trustees on 6 August 2024 and signed on its behalf by:

S B Wearing Director and Trustee

The notes on pages 26 to 36 form part of these financial statements.

www.yorkagainstcancer.org.uk 24

YORK AGAINST CANCER CONSOLIDATED CASHFLOW STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2023

Note
Cash flows from operating activities:
Net cash used in operating activities
21
Cash flows from investing activities:
Dividends, interest and rents from investments
Purchase of property, plant and equipment
Proceeds from sale of property
Proceeds from sales of investments
Purchase of investments
Net cash provided by investing activities
Change in cash and cash equivalents in the
reporting period
Cash and cash equivalents at the beginning of
the reporting period
Cash and cash equivalents at the end of
the reporting period		 2023
£
(484,244)
46,153
(405,743)
5,987
1,383,378
(860,300)
169,475
(314,769)
863,649
£ 548,880		 2022
£
(226,911)
36,438
(322,442)
-
1,475,082
(944,981)
244,097
17,186
846,463
£ 863,649

The notes on pages 26 to 36 form part of these financial statements.

www.yorkagainstcancer.org.uk 25

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

1. ACCOUNTING POLICIES

Legal entity

York Against Cancer is regulated by the Charities Commission (1130835), limited by guarantee and is registered in England and Wales. The address of the registered office and principal place of business is York Community Stadium, Kathryn Avenue, Huntington, York, England, YO32 9AF.

Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The consolidated accounts include the results of the Charitable Company and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

No separate SOFA has been presented for the Charitable Company alone as permitted by the SORP.

The Charitable Company constitutes a public benefit entity as defined by FRS 102.

The accounts are presented in UK Sterling pounds (£).

Going Concern

The Charitable Company has cash resources and has no requirement for external funding. The Directors and Trustees have a reasonable expectation that the Charitable Company has adequate resources to continue in operational existence for the foreseeable future. They continue to believe the going concern basis of accounting appropriate in preparing the annual financial statements.

Income

Donations and legacies

Credit is taken for donations and subscriptions when they are received. Credit is taken for legacies when received or if, before receipt, there is sufficient evidence to provide the necessary certainty that the legacy will be received and the value of the incoming resources can be measured with sufficient reliability.

Other trading activities

Fundraising income - represents gross income from events.

Subsidiary's non-charitable trading turnover - represents gross income from York Against Cancer Trading Company Limited, the Charitable Company's trading subsidiary.

Investments

Investment income has been accounted for on an accruals basis.

Expenditure

Raising funds

Fundraising costs - represents the total costs of fundraising events and activities held during the year.

Non charitable trading expenditure - comprises of the direct costs and administrative costs of the Charitable Company's trading subsidiary, York Against Cancer Trading Company Limited.

Charitable activities

Direct costs - comprises of expenditure on various projects the Charitable Company is supporting and is accounted for in full when the Charitable Company commits to provide the funding.

Support costs - comprises of the salaries and office expenses of the Charitable Company.

Governance costs - comprises the costs associated directly with the management by the Directors/Trustees of the Charitable Company's activities, including audit fees and costs of meetings.

All costs are apportioned on an actual cost basis.

www.yorkagainstcancer.org.uk 26

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

1. ACCOUNTING POLICIES (continued)

Pension costs

The Charitable Company operates a defined contribution money purchase pension scheme for specific employees. The assets of the scheme are invested and managed independently of the finances of the Charitable Company. The charge for pension costs represents the contributions payable in the year.

Fixed Assets

Individual fixed assets costing £200 or more are capitalised and included in the accounts at cost.

Tangible fixed assets are depreciated over their expected useful lives at the following annual rates:

Freehold/Leasehold property at straight line over 50 years or life of lease Equipment - Shop and office equipment at straight line over 10 years - Computer equipment at straight line over 3 years - Respite home equipment at straight line over 4 years - Motor vehicles at 25% reducing balance

Stock

Stock is valued at the lower of cost and net realisable value. Cost is computed on a first in first out basis. Net realisable value is based on estimated selling price less the estimated cost of disposal.

Funds Structure

Unrestricted Funds are funds which are available for use or retention at the discretion of the Directors/Trustees, in accordance with the Charity's objects. Designated Funds represent unrestricted funds earmarked by the Directors/Trustees for particular purposes. Restricted Funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal. Details of Designated and Restricted Funds are contained in Notes 16 and 17, respectively.

Investments

The investment portfolios have been valued at market value at 31 December 2023. The SOFA includes the net gains and losses on investments arising on revaluation at the year end and on disposals throughout the year. Realised gains and losses on sales of investments are calculated as the difference between the sale proceeds and opening market value. Unrealised gains and losses represent the movement between market values.

Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Cash at bank and in hand

Cash at bank and cash in hand includes cash and any short term deposit accounts with a maturity of three months or less from the date of opening.

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Operating leases

Rentals paid under operating leases are charged in the SOFA on a straight line basis over the lease term.

www.yorkagainstcancer.org.uk 27

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2023

2.
DONATIONS AND LEGACIES
In Memoriam
Legacies
Intangible income
Donations and grants		 Unrestricted
Restricted
2023
£
£
£
185,442
100
185,542
22,360
-
22,360
217,380
-
217,380
5,000
-
5,000
£ 430,182
£ 100
£ 430,282		 2022
£
228,697
26,509
909,636
5,000
£ 1,169,842

During the year the charity was notified of a potential further legacy income from various estates the timing and amounts still remain uncertain and therefore have not been provided for.

Intangible income comprises accounting services, a proportion of which is provided free of charge for the preparation of the Charitable Company and Subsidiary statutory accounts. A corresponding amount is included within governance costs.

3.
OTHER TRADING ACTIVITIES
Fundraising income
Subsidiary's non-charitable trading turnover
4.
INVESTMENTS
Interest received
Dividends received
5.
ANALYSIS OF RAISING FUNDS
Advertising
Fundraising costs
Non charitable trading - other costs
Non charitable trading - staff costs
Non charitable trading - depreciation
Investment fees		 Unrestricted
Restricted
£
£
7,097
-
109,013
-
140,780
-
43,677
-
5,404
-
15,211
-		 2023
£
129,554
157,615
£ 287,169
2023
£
5,571
40,582
£ 46,153
2023
£
7,097
109,013
140,780
43,677
5,404
15,211
£ 321,182		 2022
£
136,121
125,774
£ 261,895
2022
£
1,210
35,228
£ 36,438
2022
£
6,639
80,727
115,039
34,601
5,405
17,200
£ 321,182
£ -		 £ 259,611

www.yorkagainstcancer.org.uk 28

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

6. ANALYSIS OF CHARITABLE ACTIVITES

Direct project costs:
Research
Jack Birch Unit
Clinical Trial Nurses
Support and Care
Leveson Centre - direct
Leveson Centre -staff
Leveson Centre - depreciation
Psychology services
Complementary therapy
Respite property expenses
Minibus running costs - direct
Minibus running costs - staff costs
Mobile Chemotherapy Unit
Transport - Rapid diagnostics
Cancer benefit advice service
Robotic surgery
One off costs
Education
Education expenses
Support costs:
Staff costs
Staff training and travel
Rent, service charge and rates
Heat and light
Repairs and maintenance
Insurances
Printing, stationery and postage
Computer expenses
Telephone
Sundry expenses
Gains and losses on fixed assets
Depreciation
Governance costs:*
Audit fees
Accountancy fees
Legal and professional fees
Bank charges
Total charitable activities		 Unrestricted
Restricted
2023
£
£
£
-
-
-
5,144
-
5,144
111,384
-
111,384
53,049
-
53,049
56,287
-
56,287
16,855
-
16,855
16,212
-
16,212
29,970
-
29,970
10,311
100
10,411
22,602
-
22,602
-
20,069
20,069
4,948
-
4,948
160,000
-
160,000
-
-
-
320
-
320
-
-
-
487,082
20,169
507,251
146,138
-
146,138
4,118
-
4,118
35,885
-
35,885
4,465
-
4,465
132
-
132
5,565
-
5,565
4,271
-
4,271
11,342
-
11,342
816
-
816
8,680
-
8,680
(3,332)
-
(3,332)
25,061
-
25,061
243,141
-
243,141
7,440
-
7,440
7,760
-
7,760
5,670
-
5,670

976
-
976
21,846
-
21,846
£ 752,069
£ 20,169
£ 772,238		 2022
£
363,262
152,221
37,378
-
-
10,805
-
22,653
11,882
21,273
5,740
7,086
-
680,000
150
8,850
1,321,300
154,175
3,666
16,871
3,756
1,510
4,318
4,913
11,516
800
4,176
-
19,370
225,071
4,560
7,400
-
1,638
13,598
£ 1,559,969

www.yorkagainstcancer.org.uk 29

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

7. NET INCOMING RESOURCES FOR THE YEAR
NET INCOMING RESOURCES FOR THE YEAR 2023 2022
£ £
This is stated after charging:
Depreciation 86,752 24,775
Auditor's remuneration for audit services - charity 7,440 4,560

8. REMUNERATION AND EXPENSES OF TRUSTEES

None of the Trustees received any remuneration or benefits by virtue of being a trustee of the Charity and no Trustees were reimbursed any expenses incurred for services provided to the Charity.

9. STAFF COSTS

AFF COSTS
Wages and salaries
Social security costs
Pension costs
Recruitment costs
Medical Insurance
Sub-contractor costs		 2023
£
237,607
15,396
8,550
930
2,517
6,424
£ 271,424		 2022
£
185,048
11,194
7,602
3,120
3,085
-
£ 210,049

The average monthly head count was 10 staff (2022 8) and the average monthly number of full-time equivalent employees (including casual and part-time staff) during the year were as follows:

ual and part-time staff) during the year were as follows:
Projects 2 1
Trading 2 1
Management and administration 6 6

No employee received emoluments in excess of £60,000.

The key management personnel of the Charitable Company, comprise the directors and trustees, the CEO and Deputy CEO following the restructure. The total employee benefits of the key management personnel of the Charitable Company were £93,271 (2022 - £88,871).

10. SUBSIDIARY COMPANY

The Charitable Company owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited. This company is registered in England and Wales (reg. no. 3405708) and its registered office is York Community Stadium, Kathryn Avenue, Huntington, York, England, YO32 9AF. The subsidiary is used for the raising of funds for the Charitable Company through the sale of bought in goods through the Charitable Company's shop and stalls. All activities have been consolidated on a line by line basis in the

There is a loan account between the Charitable Company and the subsidiary. The balance on the loan account outstanding at the year end was £149,404 (2022 £138,024). Interest of £nil (2022 £nil) was charged during the year in respect of this loan.

A summary of the results of the subsidiary is shown below:

ummary of the results of the subsidiary is shown below:
Turnover
Cost of sales
Gross profit
Administrative expenses
Operating profit
Profit on ordinary activities before taxation
Taxation
Profit on ordinary activities after taxation
Amount gifted to York Against Cancer
Retained (withdrawn from)/within Subsidiary
Net Assets		 2023
£
160,310
(82,637)
77,673
(107,224)
(29,551)
(29,551)
-
(29,551)
-
£ (29,551)
£ (43,950)		 2022
£
125,774
(61,578)
64,196
(93,467)
(29,271)
(29,271)
-
(29,271)
-
£ (29,271)
£ (14,339)

www.yorkagainstcancer.org.uk 30

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2023

11. INVESTMENTS

ESTMENTS
Consolidated
Market value at 1 January 2023
Additions at cost
Disposals
Revaluations
Market value at 31 December 2023
Analysis of investments by class:
Listed investments
The historical cost of the above investments amounts to:		 2023
£
3,516,497
860,300
(1,383,378)
(6,362)
£ 2,987,057
£ 2,987,057
£ 2,710,556		 2022
£
4,076,184
944,981
(1,475,082)
(29,586)
£ 3,516,497
£ 3,516,497
£ 3,196,719

The following material investments are over 5% by value of the investments held

Ruffer Charity Assets Trust Account 2023
Market value
£
1,611,882
£ 1,611,882		 2022
Market value
£
1,832,547
£ 1,832,547

The Charitable Company holds all of the issued shares of its subsidiary undertaking York Against Cancer Trading Company Limited, at cost of £1, in addition to the above investments.

12. TANGIBLE FIXED ASSETS

TANGIBLE FIXED ASSETS
Cost
Additions in year
Disposals in year
At 31 December 2023
At 31 December 2023
Depreciation
At 31 December 2022
At 1 January 2023
Charge for year
Disposals in year
At 31 December 2023
Net book value
At 1 January 2023		 Subsidiary -
Motor
Charity
Shop
Property
Vehicles
Equipment
Total
Equipment
£
£
£
£
£
799,930
88,451
43,843
932,224
54,048
246,434
-
10,019
256,453
-
-
(26,515)
-
(26,515)
-
1,046,364
61,936
53,862
1,162,162
54,048
44,125
43,222
18,636
105,983
14,059
63,641
10,518
7,189
81,348
5,404
-
(23,860)
-
(23,860)
-
107,766
29,880
25,825
163,471
19,463
£ 938,598
£ 32,056
£ 28,037
£ 998,691
£ 34,585
£ 755,805
£ 45,229
£ 25,207
£ 826,241
£ 39,989		 Consolidated
Total
£
986,272
256,453
(26,515)
1,216,210
120,042
86,752
(23,860)
182,934
£ 1,033,276
£ 866,230

All fixed assets are held for direct charitable purposes in Designated Funds.

www.yorkagainstcancer.org.uk 31

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

13.
Amounts owed by subsidiary
Prepayments
Accrued income
Other debtors
14. CREDITORS: amounts falling due
within one year
Trade creditors
Project creditors
Taxation and social security
Accruals
Other creditors
15. CREDITORS: amounts falling due
after one year
Project creditors
16. DESIGNATED FUNDS (consolidated)
DEBTORS		 Charity
Consolidated
Charity
Consolidated
2023
2023
2022
2022
£
£
£
£
149,404
-
138,024
-
34,138
41,069
13,396
20,272
542,913
542,913
892,405
892,405
-
-
-
-
£ 726,455
£ 583,982
£ 1,043,825
£ 912,677
14,785 24,562 176,204 182,320
891,796
891,796 827,466
827,466
6,484
16,656 3,802
4,201
98,459
142,194 45,342
74,362
3,015
3,015
2,746
2,746
£ 1,014,539
£ 1,078,223
£ 1,055,560
£ 1,091,095
£ 80,000
£ 80,000
£ 731,410
£ 731,410
Designated Funds - 2023
Leveson Centre
On demand services
Education Project
Health Welfare
Jack Birch Unit
Robotic Surgery Project
Fixed Assets Fund
Total
Designated Funds - 2022
Leveson Centre
On demand services
Education Project
Minibus
Health Welfare
Jack Birch Unit
Robotic Surgery Project
Fixed Assets Fund
Total		 Balance
Income
Expenditure
Transfers
Balance
01/01/2023
31/12/2023
£
£
£
£
£
553,750
-
(60,750)
(250,000)
243,000
66,000
-
(36,780)
36,780
66,000
10,000
-
-
-
10,000
114,000
-
(114,000)
-
-
1,500,000
-
-
-
1,500,000
-
-
-
-
-
866,230
-
(83,419)
250,465
1,033,276
£ 3,109,980
£ -
£ (294,949)
£ 37,245
£ 2,852,276
Balance
Income
Expenditure
Transfers
Balance
01/01/2022
31/12/2022
£
£
£
£
£
466,500
-
-
87,250
553,750
10,000
-
(7,086)
63,086
66,000
-
-
(8,850)
18,850
10,000
36,000
-
-
(36,000)
-
-
-
-
114,000
114,000
-
-
-
1,500,000
1,500,000
680,000
-
-
(680,000)
-
405,171
-
(24,775)
485,834
866,230
£ 1,597,671
£ -
£ (40,711)
£ 1,553,020
£ 3,109,980

Leveson Centre

The charity has set aside the remaining budget for improvements relating to the Leveson Centre as the year end and 5 years of lease costs.

www.yorkagainstcancer.org.uk 32

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2023

16.[DESIGNATED FUNDS (consolidated continued)]

On demand services

The trustees have set aside monies to fund the following on demand services - patient travel for rapid diaognositics, complementary therapy and teenage psychology services. These services levels are set budgets at the beginning of each year based on current demand.

Education Project

The Board agreed to fund the annual budgeted costs of the Education Project which is aimed at raising the awareness of cancer to the public.

Minibus

The trustees have set aside monies for the purchase of a new minibus which was purchased in 2022.

Health Welfare

The board wish to fund an additional health welfare post for 3 years in the York area and have ring fenced the following monies.

Jack Birch Unit

The Jack Birch Unit grant is up for renewal in 2024 and the trustees wish to continue this support the on-going research. Investments of £1.5m has been designated to ensure the charity can fund the continued support in 2024.

Robotic Surgery Project

During the year the charity committed to support the NHS regarding its Robotic Surgery facilities. The commitment of £680,000 has been recognised in 2022 and will be paid over 3 years.

Fixed Asset Fund

This fund represents funds invested in tangible fixed assets.

17. RESTRICTED FUNDS (consolidated)

Restricted Funds - 2023
Mobile Chemotherapy Unit
Minibus Appeal
Mouth Cancer
Total 2023
Restricted Funds - 2022
Mobile Chemotherapy Unit
Minibus Appeal
Jack Birch Unit
Mouth Cancer
Total 2022		 Balance
Income
Expenditure
Transfers
Balance
01/01/2023
31/12/2023
£
£
£
£
£
133,726
-
(20,069)
-
113,657
-
100
(100)
-
-
1,677
-
-
-
1,677
£ 135,403
£ 100
(£ 20,169)
£ -
£ 115,334
Balance
Income
Expenditure
Transfers
Balance
01/01/2022
31/12/2022
£
£
£
£
£
136,966
2,500
(5,740)
-
133,726
-
2,500
-
(2,500)
-
-
10,000
(10,000)
-
-
1,677
-
-
-
1,677
£ 138,643
£ 15,000
(£ 15,740)
(£ 2,500)
£ 135,403

Mobile Chemotherapy Unit

The Mobile Chemotherapy Unit Appeal relates to funds raised for the specific purpose of running the service.

Minibus Appeal

Monies were received for the running costs of the minibus in 2023 and the purchase of the new minibus which was in 2022.

Jack Birch Unit

Monies were received for support of the Jack Birch Unit which were used during 2022.

Mouth Cancer

Monies raised for the Head and Neck cancer department.

www.yorkagainstcancer.org.uk 33

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

18. ANALYSIS OF GROUP NET ASSETS BETWEEN FUNDS

Fund balances at 31 December 2023
are represented by:
Tangible fixed assets
Investments
Current assets
Current liabilities
Long term liabilities
Fund balances at 31 December 2022
are represented by:
Tangible fixed assets
Investments
Current assets
Current liabilities
Long term liabilities		 General
Designated
Restricted
Total
Funds
Funds
Funds
2023
£
£
£
£
-
1,033,276
-
1,033,276
1,487,057
1,500,000
-
2,987,057
764,447
319,000
115,334
1,198,781
(1,078,223)
-
-
(1,078,223)
(80,000)
-
-
(80,000)
£ 1,093,281
£ 2,852,276
£ 115,334
£ 4,060,891
General
Designated
Restricted
Total
Funds
Funds
Funds
2022
£
£
£
£
-
866,230
-
866,230
3,516,497
-
-
3,516,497
1,651,698
49,746
135,403
1,836,847
(1,091,095)
-
-
(1,091,095)
(731,410)
-
-
(731,410)
£ 3,345,690
£ 915,976
£ 135,403
£ 4,397,069

19. OPERATING LEASE COMMITMENTS

As at 31 December 2023 the group had the total minimum lease payments under operating leases at the end of the reporting period, for each of the following period:

At 31 December 2023 At 31 December 2023 At 31 December 2022 At 31 December 2022
Land and Office Land and Office
buildings equipment buildings equipment
Total operating leases payable: £ £ £ £
Within one year 115,905 - 115,905 -
Between two and five years 312,714 - 335,370 -
After five years 210,094 - 278,273 -

20. RELATED PARTIES

During the year the Charitable Company paid £3,182 (2022 £3,097) to HPH Chartered Accountants for accountancy services and software costs, a firm in which the Charitable Company's Treasurer, Sarah Wearing, is a partner. At the year end there was £nil (2022 £nil) owing to HPH Chartered Accountants.

During 2023 trustees and related parties donated £6,100 (2022 - £116,384) to the charity.

www.yorkagainstcancer.org.uk 34

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

21. CASH FLOW NOTES

Net income/(expenditure) for the reporting period
Adjustments for:
Depreciation charges
Gains on sale of fixed assets
(Gains)/Losses on investments
Dividends, interest and rents from investments
(Increase)/Decrease in stocks
(Increase)/Decrease in debtors
Increase/(Decrease) in creditors
Net cash used in operating activities
ANALYSIS OF CASH AND CASH EQUIVALENTS
Cash at bank and in hand
Total cash and cash equivalents
ANALYSIS OF CHANGES IN NET DEBT
At
01/01/2023
£
Cash
863,649
RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING
ACTIVITIES		 2023
2022
£
£
(336,178)
(380,991)
86,752
24,775
(3,332)
-
6,362
29,586
(46,153)
(36,438)
(5,398)
(5,345)
328,695
(462,906)
(514,992)
604,408
£ (484,244)
£ (226,911)
548,880
863,649
£ 548,880
£ 863,649
At
Cash-flows
31/12/2023
£
£
(314,769)
548,880

22. VOLUNTEERS

The Charity is fortunate to be supported by over 100 volunteers. Their activities include working in our shops, attending events, supporting the office, collections and baking. Without them the Charity could not achieve what it does; their support is a massive asset in both workforce and financial terms. Whilst going about their work they are also ambassadors for the Charity which encourages more people to volunteer and support.

With varied knowledge, skills and experience the volunteers make an invaluable group. Our thanks goes to them all – together we really do make a difference to cancer patients and their families.

www.yorkagainstcancer.org.uk 35

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

24. COMPARATIVE INFORMATION

Income and endowments from:
Donations and legacies
Other trading activities
Investments
Total
Expenditure on:
Raising funds
Charitable activities
Total
Net expenditure
before losses on investments
Net gains on investments
Net income/(expenditure)
Transfers between funds
Net movement in funds
Reconciliation of funds:
Total funds brought forward
Total funds carried forward		 General
Designated
Fund
Funds
£
£
1,154,842
-
261,895
-
36,438
-
1,453,175
-
259,611
-
1,503,518
40,711
1,763,129
40,711
(309,954)
(40,711)
(29,586)
-
(339,540)
(40,711)
(1,550,520)
1,553,020
(1,890,060)
1,512,309
3,041,746
1,597,671
£ 1,151,686
£ 3,109,980
Unrestricted		 Restricted
Funds
£
15,000
-
-
15,000
-
15,740
15,740
(740)
-
(740)
(2,500)
(3,240)
138,643
£ 135,403		 Year ended
31 Dec
2022
£
1,169,842
261,895
36,438
1,468,175
259,611
1,559,969
1,819,580
(351,405)
(29,586)
(380,991)
-
(380,991)
4,778,060
£ 4,397,069

25. CAPITAL COMMITMENTS

At the year end the charity was committed to spend £nil (2022- £250,000) for the completion of the Leveson Centre fit out. The Leveson Centre fit out was completed in the year.

www.yorkagainstcancer.org.uk 36